149 related articles for article (PubMed ID: 24650702)
1. Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity.
Yamakawa N; Suzuki K; Yamashita Y; Katsu T; Hanaya K; Shoji M; Sugai T; Mizushima T
Bioorg Med Chem; 2014 Apr; 22(8):2529-34. PubMed ID: 24650702
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.
Habeeb AG; Praveen Rao PN; Knaus EE
J Med Chem; 2001 Aug; 44(18):3039-42. PubMed ID: 11520213
[TBL] [Abstract][Full Text] [Related]
3. Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.
Ermondi G; Caron G; Lawrence R; Longo D
J Comput Aided Mol Des; 2004 Nov; 18(11):683-96. PubMed ID: 15865061
[TBL] [Abstract][Full Text] [Related]
4. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of loxoprofen derivatives.
Yamakawa N; Suemasu S; Matoyama M; Tanaka K; Katsu T; Miyata K; Okamoto Y; Otsuka M; Mizushima T
Bioorg Med Chem; 2011 Jun; 19(11):3299-311. PubMed ID: 21570308
[TBL] [Abstract][Full Text] [Related]
6. Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: synthesis and biological studies.
Bhardwaj A; Kaur J; Wuest F; Knaus EE
ChemMedChem; 2014 Jan; 9(1):109-16, 240. PubMed ID: 24376205
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.
Navidpour L; Amini M; Shafaroodi H; Abdi K; Ghahremani MH; Dehpour AR; Shafiee A
Bioorg Med Chem Lett; 2006 Sep; 16(17):4483-7. PubMed ID: 16806914
[TBL] [Abstract][Full Text] [Related]
8. New celecoxib derivatives as anti-inflammatory agents.
Szabó G; Fischer J; Kis-Varga A; Gyires K
J Med Chem; 2008 Jan; 51(1):142-7. PubMed ID: 18072726
[TBL] [Abstract][Full Text] [Related]
9. [Coxibs: cyclooxygenase-2 inhibitors].
Turnheim K
Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
Praveen Rao PN; Amini M; Li H; Habeeb AG; Knaus EE
J Med Chem; 2003 Nov; 46(23):4872-82. PubMed ID: 14584938
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of N-benzenesulfonamide-1H-pyrazoles bearing arylsulfonyl moiety: novel celecoxib analogs as potent anti-inflammatory agents.
Abdel-Aziz HA; Al-Rashood KA; ElTahir KE; Suddek GM
Eur J Med Chem; 2014 Jun; 80():416-22. PubMed ID: 24794773
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
[TBL] [Abstract][Full Text] [Related]
13. [Gastrointestinal damage induced by celecoxib and rofecoxib in rats].
Laudanno OM; Cesolari JA; Esnarriaga J; Rista L; Piombo G; Maglione C; Aramberry LJ; Sambrano JS; Godoy A; Rocaspana A
Acta Gastroenterol Latinoam; 2000; 30(1):27-33. PubMed ID: 10855352
[TBL] [Abstract][Full Text] [Related]
14. Kinetic basis for selective inhibition of cyclo-oxygenases.
Gierse JK; Koboldt CM; Walker MC; Seibert K; Isakson PC
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):607-14. PubMed ID: 10215599
[TBL] [Abstract][Full Text] [Related]
15. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
16. Are rofecoxib and celecoxib safer NSAIDS?
Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
[TBL] [Abstract][Full Text] [Related]
17. Tracing the origins of COX-2 inhibitors' structures.
Lednicer D
Curr Med Chem; 2002 Aug; 9(15):1457-61. PubMed ID: 12173976
[TBL] [Abstract][Full Text] [Related]
18. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
Hudson M; Richard H; Pilote L
BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Anti-Inflammatory Activity, and COX-1/2 Inhibition Profile of Some Novel Non-Acidic Polysubstituted Pyrazoles and Pyrano[2,3-c]pyrazoles.
Faidallah HM; Rostom SAF
Arch Pharm (Weinheim); 2017 May; 350(5):. PubMed ID: 28370254
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
